ABSTRACT
Uno de los tratamientos considerado altamente eficaz para el vitíligo es la fototerapia UVB de banda estrecha, pero sus efectos adversos limitan su uso. Por otro lado el Polypodium leucotomos con acciones fotoinmunoprotectora y antioxidante, disminuye la fototoxicidad de la radiación ultravioleta. El objetivo de este estudio es determinar si P. leucotomos: bloquea o aumenta el efecto terapéutico de UVB de banda estrecha. Es un ensayo clínico doble ciego que incluye pacientes con vitíligo a quienes se les indica fototerapia UVB de banda estrecha. Trece pacientes con vití-ligo ingresan al estudio. La media de edad en años fue 27 ± 12. La media del tiempo de evolución de la enfermedad fue de 8 ± 10 meses. De los 13pacientes, 8 (62%) terminan el estudio, de los cuales, 4 recibieron el Polypodium leucotomos (Grupo A) y 4 recibieron placebo (Grupo B). Los pacientes del grupo A, iniciaron con una media de despigmentación de 26 ± 13% y terminaron con 6 ± 4% de despigmentación, alcanzando una media derepigmentación de 76,93%; mientras que los pacientes del grupo B iniciaron con una media de despigmentación de 35 ± 21% y terminaron con una media de despigmentación de 16 ± 17%, con una media de repigmentación de 54,29%.Creemos que podemos emplear el Polypodium leucotomos, acompañando a cualquier terapia UV ya que sus efectos terapéuticos no se ven afectados y al contrario se agrega el beneficio de disminuir la fototoxicidad, especialmente en vitíligo porque el Polypodium leucotomos aportaría con sus acciones inmumoduladoras beneficio a la repigmentación (AU)
One of the considered highly efficient treatments against vitiligo is narrow band UV-B phototherapy, but their adverse effects limit its use. On the other hand, Polypodium leucotomos with photoimmunoprotection and antioxidant actions decrease the phototoxicity of the ultraviolet radiation. The objective of this study is to determine if P. leucotomos: blocks or increase the therapeutic effect of the UV-B narrow band. This is a double blind clinical study that involves patients with vitiligo which UV-B narrow band phototherapy has been prescribed. Thirteen patients with vitiligo were enrolled to the study. The mean of age was 27 ± 12. The mean of the number of spots was 8 ± 6. The mean of the evolution time was8 ± 10 months. From the thirteen patients, five patients (38%) dropped out the research and 8 (62%) finished it. From the 8 patients who finished the study, 4 received P. leucotomos (grup A) and 4 received placebo (grup B). The group A started with a mean of depigmentation area of 35 ± 21%, and finished with a mean of depigmentation of 16 ± 17%. The group B started with a depigmentation mean of 26 ± 13% and finished with 6 ± 4%.We believe that we could employ the P. leucotomos, combined with any ultraviolet therapy due to its therapeutic effects are not affected, and it adds the benefit to diminish the phototoxicity, specially in vitiligo because P. leucotomos would contribute with its immunomodulating actions (AU)
Subject(s)
Humans , Vitiligo/drug therapy , Polypodium , Plant Extracts/pharmacokinetics , Ultraviolet Therapy/methods , Chemotherapy, Adjuvant/methods , Dermatitis, Phototoxic/prevention & control , Protective Agents/pharmacokinetics , ImmunomodulationABSTRACT
Microinjections of the irreversible dopamine antagonist EEDQ (N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline), into nucleus accumbens but not into dorsal striatum, markedly decreased response rates on a fixed interval schedule of reinforcement. These preferential effects in nucleus accumbens could be prevented by selectively activating either D1 or D2 receptors. These data demonstrate a critical role for mesolimbic dopamine systems in the mediation of fixed interval schedule-controlled operant behavior.
Subject(s)
Conditioning, Operant/physiology , Dopamine/physiology , Nucleus Accumbens/physiology , Animals , Dopamine Antagonists/pharmacology , Male , Microinjections , Quinolines/pharmacology , Rats , Receptors, Dopamine D1/agonists , Receptors, Dopamine D2/agonists , Reinforcement ScheduleABSTRACT
Subarachnoid hemorrhage as a result of superimposed preeclamptic toxemia is a well-known complication but fortunately not a common one. The maternal and fetal mortality rates are high. In one such patient the outcome for both mother and infant was excellent.
